Therefore, whether the mitochondrial dynamics modulators used in basic experiments, such as Mdivi-1, an inhibitor of Drp1, and P110, an adapter-specific inhibitor of Drp1/Fis1 interaction discovered in recent years, can be used for the treatment of related cardiovascular diseases still needs to be verified by numerous clinical studies, and their related toxicological and pharmacokinetic characteristics still need to be further investigated. Here, FIS1 is linked to cardiovascular disorder.